Bausch + Lomb today announced it received Health Canada approval for its enVista Envy full visual range intraocular lens. The Health Canada nod is the first regulatory approval of the new lens that offers a full range of vision with dysphotopsia tolerance on the enVista IOL platform. “enVista Envy is the next step in the […]
Bausch + Lomb
Bausch+Lomb launches $1.4B offering to finance XIIDRA eye drop buy
Bausch + Lomb (NYSE:BLCO) announced today that it launched an offering worth $1.4 billion in new senior secured notes. The company intends to offer the notes, due 2028, and to enter into an incremental term loan facility. Both moves aim to support the financing of the company’s pending acquisition of XIIDRA. Bausch + Lomb expects […]
Bausch + Lomb makes another eye drop acquisition
Bausch + Lomb (NYSE:BLCO) announced today that an affiliate purchased the Blink product line from Johnson & Johnson Vision. The over-the-counter Blink product line features eye and contact lens drops, marking another eye care acquisition for Bausch + Lomb. Last week, the company acquired eye drops and a delivery system from Novartis in a deal worth up to […]
Bausch + Lomb acquires XIIDRA eye drops, delivery system from Novartis in $2.5B deal
Bausch + Lomb (NYSE:BLCO) announced today that it agreed to acquire XIIDRA non-steroid eye drops from Novartis. The company also acquired an investigational medicine and rights to a delivery device for treating dry eye disease (DED). AcuStream, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical […]
Bausch + Lomb names Brent Saunders as new CEO
Bausch + Lomb (NYSE:BLCO) announced today that it appointed Brent Saunders as CEO and chair of its board of directors. Saunders succeeds Joseph C. Papa in the role, effective March 6, 2023. Papa announced his intention to step down in July 2022. When Papa announced his plans to depart, the optical and ophthalmic device maker […]
Bausch + Lomb buys AcuFocus and its intraocular lens tech
Bausch + Lomb (NYSE:BLCO) announced that its affiliate acquired AcuFocus, a privately held maker of ophthalmic medical devices. The deal remains pursuant to a merger transaction with the parent company of AcuFocus. Neither company disclosed the financial terms of the transaction. AcuFocus develops small aperture intraocular technology. Its portfolio includes the IC-8 Apthera intraocular lens […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Bausch Health takes step toward separating Bausch+Lomb
Bausch Health (NYSE:BHC) announced today that it transferred shares of its Bausch + Lomb to an existing subsidiary. The Laval, Quebec–based company transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing, wholly-owned, unrestricted subsidiary of the company. According to a news […]
The biggest medtech personnel moves so far in 2022
In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit. At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. So far in 2022, we’ve already seen a slew of major moves involving some of the space’s most powerful […]
Bausch + Lomb CEO to step down
Bausch + Lomb (NYSE:BLCO) announced today that Joseph C. Papa will step down as the company’s board chair and CEO. The optical and ophthalmic device maker has appointed Thomas W. Ross, Sr., to serve as its chair and has begun the search for a new CEO. Papa will remain as CEO and a member of […]
Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.
Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the therapy to […]
